Acer therapeutics and relief therapeutics announce presentation of acer-001 data at the society for inherited metabolic disorders annual meeting

Newton, mass. and geneva, april 12, 2022 (globe newswire) -- acer therapeutics inc. (nasdaq: acer) (“acer”) and its collaboration partner, relief therapeutics holding sa (six: rlf, otcqb: rlftf, rlfty) (“relief”), today announced the presentation of data evaluating the bioavailability, bioequivalence and taste attributes of taste-masked sodium phenylbutyrate (acer-001) compared to sodium phenylbutyrate (buphenyl®) powder during poster sessions at the recent society for inherited metabolic disorders (simd) annual meeting on april 10-13, 2022 in orlando, florida.
ACER Ratings Summary
ACER Quant Ranking